Table 2 Open in new tab Univariate and...

Outcome predictor	PP	SP
Statins	0.57 (0.43–0.75)	0.65 (0.48–0.88)	0.47 (0.38–0.58)	0.66 (0.52–0.84)
Age	1.05 (1.03–1.06)	1.04 (1.03–1.06)	1.03 (1.02–1.04)	1.02 (1.00–1.03)
Male/female	1.06 (0.81–1.40)	1.14 (0.85–1.53)	0.83 (0.67–1.02)	0.89 (0.71–1.12)
Baseline TC concentration (mmol/l)	0.99 (0.89–1.10)	1.08 (0.96–1.21)	1.00 (0.94–1.08)	1.00 (0.92–1.08)
Social economic status
1 (most deprived)	1.00	1.00	1.00	1.00
2–3	0.63 (0.45–0.87)	0.54 (0.38–0.75)	1.08 (0.85–1.37)	0.96 (0.75–1.22)
4–5 (most affluent)	0.78 (0.55–1.08)	0.62 (0.44–0.88)	0.85 (0.65–1.11)	0.78 (0.59–1.02)
Concurrent use of drugs
Analgesics	0.64 (0.48–0.85)	0.69 (0.50–0.94)	0.49 (0.40–0.61)	0.50 (0.40–0.63)
Positive inotropic drugs	1.94 (1.33–2.83)	1.71 (1.11–2.61)	1.28 (1.03–1.60)	0.99 (0.77–1.29)
Diuretics	0.95 (0.70–1.27)	0.86 (0.61–1.21)	0.96 (0.72–1.27)	1.10 (0.81–1.49)
Antiarrhythmic drugs	1.11 (0.46–2.69)	0.71 (0.29–1.78)	0.80 (0.54–1.19)	0.70 (0.47–1.05)
β-Adrenoceptor blocking drugs	0.79 (0.60–1.05)	0.78 (0.58–1.05)	0.51 (0.41–0.63)	0.59 (0.47–0.75)
Hypertension and HF	0.67 (0.51–0.88)	0.82 (0.60–1.21)	0.55 (0.44–0.68)	0.70 (0.55–0.88)
Nitrates and calcium-channel blockers	0.85 (0.64–1.13)	1.03 (0.75–1.41)	0.62 (0.49–0.79)	0.95 (0.73–1.23)
Anticoagulants	1.14 (0.79–1.64)	1.01 (0.67–1.53)	0.94 (0.74–1.19)	0.82 (0.61–1.10)
Antiplatelet drugs	1.29 (0.97–1.70)	1.24 (0.91–1.68)	0.64 (0.51–0.80)	0.74 (0.56–0.98)
Corticosteroids	0.51 (0.37–0.70)	0.68 (0.49–0.95)	0.65 (0.52–0.83)	0.77 (0.60–0.98)
NSAIDs	0.50 (0.34–0.73)	0.52 (0.35–0.77)	0.57 (0.43–0.75)	0.67 (0.51–0.89)
Comorbidity
Diabetes mellitus	0.80 (0.58–1.11)	0.86 (0.61–1.21)	0.97 (0.77–1.21)	1.04 (0.82–1.31)
Angina, TIA and HF	2.36 (1.65–3.39)	2.45 (1.68–3.58)	1.45 (1.18–1.78)	1.96 (1.56–2.46)

Outcome predictor

Unadjusted HR

Adjusted HR

Unadjusted HR

Adjusted HR

Statins

0.57 (0.43–0.75)

0.65 (0.48–0.88)

0.47 (0.38–0.58)

0.66 (0.52–0.84)

Age

1.05 (1.03–1.06)

1.04 (1.03–1.06)

1.03 (1.02–1.04)

1.02 (1.00–1.03)

Male/female

1.06 (0.81–1.40)

1.14 (0.85–1.53)

0.83 (0.67–1.02)

0.89 (0.71–1.12)

Baseline TC concentration (mmol/l)

0.99 (0.89–1.10)

1.08 (0.96–1.21)

1.00 (0.94–1.08)

1.00 (0.92–1.08)

Social economic status

1 (most deprived)

1.00

2–3

0.63 (0.45–0.87)

0.54 (0.38–0.75)

1.08 (0.85–1.37)

0.96 (0.75–1.22)

4–5 (most affluent)

0.78 (0.55–1.08)

0.62 (0.44–0.88)

0.85 (0.65–1.11)

0.78 (0.59–1.02)

Concurrent use of drugs

Analgesics

0.64 (0.48–0.85)

0.69 (0.50–0.94)

0.49 (0.40–0.61)

0.50 (0.40–0.63)

Positive inotropic drugs

1.94 (1.33–2.83)

1.71 (1.11–2.61)

1.28 (1.03–1.60)

0.99 (0.77–1.29)

Diuretics

0.95 (0.70–1.27)

0.86 (0.61–1.21)

0.96 (0.72–1.27)

1.10 (0.81–1.49)

Antiarrhythmic drugs

1.11 (0.46–2.69)

0.71 (0.29–1.78)

0.80 (0.54–1.19)

0.70 (0.47–1.05)

β-Adrenoceptor blocking drugs

0.79 (0.60–1.05)

0.78 (0.58–1.05)

0.51 (0.41–0.63)

0.59 (0.47–0.75)

Hypertension and HF

0.67 (0.51–0.88)

0.82 (0.60–1.21)

0.55 (0.44–0.68)

0.70 (0.55–0.88)

Nitrates and calcium-channel blockers

0.85 (0.64–1.13)

1.03 (0.75–1.41)

0.62 (0.49–0.79)

0.95 (0.73–1.23)

Anticoagulants

1.14 (0.79–1.64)

1.01 (0.67–1.53)

0.94 (0.74–1.19)

0.82 (0.61–1.10)

Antiplatelet drugs

1.29 (0.97–1.70)

1.24 (0.91–1.68)

0.64 (0.51–0.80)

0.74 (0.56–0.98)

Corticosteroids

0.51 (0.37–0.70)

0.68 (0.49–0.95)

0.65 (0.52–0.83)

0.77 (0.60–0.98)

NSAIDs

0.50 (0.34–0.73)

0.52 (0.35–0.77)

0.57 (0.43–0.75)

0.67 (0.51–0.89)

Comorbidity

Diabetes mellitus

0.80 (0.58–1.11)

0.86 (0.61–1.21)

0.97 (0.77–1.21)

1.04 (0.82–1.31)

Angina, TIA and HF

2.36 (1.65–3.39)

2.45 (1.68–3.58)

1.45 (1.18–1.78)

1.96 (1.56–2.46)

Outcome predictor	PP	SP
Statins	0.57 (0.43–0.75)	0.65 (0.48–0.88)	0.47 (0.38–0.58)	0.66 (0.52–0.84)
Age	1.05 (1.03–1.06)	1.04 (1.03–1.06)	1.03 (1.02–1.04)	1.02 (1.00–1.03)
Male/female	1.06 (0.81–1.40)	1.14 (0.85–1.53)	0.83 (0.67–1.02)	0.89 (0.71–1.12)
Baseline TC concentration (mmol/l)	0.99 (0.89–1.10)	1.08 (0.96–1.21)	1.00 (0.94–1.08)	1.00 (0.92–1.08)
Social economic status
1 (most deprived)	1.00	1.00	1.00	1.00
2–3	0.63 (0.45–0.87)	0.54 (0.38–0.75)	1.08 (0.85–1.37)	0.96 (0.75–1.22)
4–5 (most affluent)	0.78 (0.55–1.08)	0.62 (0.44–0.88)	0.85 (0.65–1.11)	0.78 (0.59–1.02)
Concurrent use of drugs
Analgesics	0.64 (0.48–0.85)	0.69 (0.50–0.94)	0.49 (0.40–0.61)	0.50 (0.40–0.63)
Positive inotropic drugs	1.94 (1.33–2.83)	1.71 (1.11–2.61)	1.28 (1.03–1.60)	0.99 (0.77–1.29)
Diuretics	0.95 (0.70–1.27)	0.86 (0.61–1.21)	0.96 (0.72–1.27)	1.10 (0.81–1.49)
Antiarrhythmic drugs	1.11 (0.46–2.69)	0.71 (0.29–1.78)	0.80 (0.54–1.19)	0.70 (0.47–1.05)
β-Adrenoceptor blocking drugs	0.79 (0.60–1.05)	0.78 (0.58–1.05)	0.51 (0.41–0.63)	0.59 (0.47–0.75)
Hypertension and HF	0.67 (0.51–0.88)	0.82 (0.60–1.21)	0.55 (0.44–0.68)	0.70 (0.55–0.88)
Nitrates and calcium-channel blockers	0.85 (0.64–1.13)	1.03 (0.75–1.41)	0.62 (0.49–0.79)	0.95 (0.73–1.23)
Anticoagulants	1.14 (0.79–1.64)	1.01 (0.67–1.53)	0.94 (0.74–1.19)	0.82 (0.61–1.10)
Antiplatelet drugs	1.29 (0.97–1.70)	1.24 (0.91–1.68)	0.64 (0.51–0.80)	0.74 (0.56–0.98)
Corticosteroids	0.51 (0.37–0.70)	0.68 (0.49–0.95)	0.65 (0.52–0.83)	0.77 (0.60–0.98)
NSAIDs	0.50 (0.34–0.73)	0.52 (0.35–0.77)	0.57 (0.43–0.75)	0.67 (0.51–0.89)
Comorbidity
Diabetes mellitus	0.80 (0.58–1.11)	0.86 (0.61–1.21)	0.97 (0.77–1.21)	1.04 (0.82–1.31)
Angina, TIA and HF	2.36 (1.65–3.39)	2.45 (1.68–3.58)	1.45 (1.18–1.78)	1.96 (1.56–2.46)

Table 2

Open in new tab

Univariate and multivariate analyzes in the PP and SP of CVD

Outcome predictor	PP		SP
Outcome predictor	Unadjusted HR	Adjusted HR	Unadjusted HR	Adjusted HR

Statins	0.57 (0.43–0.75)	0.65 (0.48–0.88)	0.47 (0.38–0.58)	0.66 (0.52–0.84)
Age	1.05 (1.03–1.06)	1.04 (1.03–1.06)	1.03 (1.02–1.04)	1.02 (1.00–1.03)
Male/female	1.06 (0.81–1.40)	1.14 (0.85–1.53)	0.83 (0.67–1.02)	0.89 (0.71–1.12)
Baseline TC concentration (mmol/l)	0.99 (0.89–1.10)	1.08 (0.96–1.21)	1.00 (0.94–1.08)	1.00 (0.92–1.08)
Social economic status
1 (most deprived)	1.00	1.00	1.00	1.00
2–3	0.63 (0.45–0.87)	0.54 (0.38–0.75)	1.08 (0.85–1.37)	0.96 (0.75–1.22)
4–5 (most affluent)	0.78 (0.55–1.08)	0.62 (0.44–0.88)	0.85 (0.65–1.11)	0.78 (0.59–1.02)
Concurrent use of drugs
Analgesics	0.64 (0.48–0.85)	0.69 (0.50–0.94)	0.49 (0.40–0.61)	0.50 (0.40–0.63)
Positive inotropic drugs	1.94 (1.33–2.83)	1.71 (1.11–2.61)	1.28 (1.03–1.60)	0.99 (0.77–1.29)
Diuretics	0.95 (0.70–1.27)	0.86 (0.61–1.21)	0.96 (0.72–1.27)	1.10 (0.81–1.49)
Antiarrhythmic drugs	1.11 (0.46–2.69)	0.71 (0.29–1.78)	0.80 (0.54–1.19)	0.70 (0.47–1.05)
β-Adrenoceptor blocking drugs	0.79 (0.60–1.05)	0.78 (0.58–1.05)	0.51 (0.41–0.63)	0.59 (0.47–0.75)
Hypertension and HF	0.67 (0.51–0.88)	0.82 (0.60–1.21)	0.55 (0.44–0.68)	0.70 (0.55–0.88)
Nitrates and calcium-channel blockers	0.85 (0.64–1.13)	1.03 (0.75–1.41)	0.62 (0.49–0.79)	0.95 (0.73–1.23)
Anticoagulants	1.14 (0.79–1.64)	1.01 (0.67–1.53)	0.94 (0.74–1.19)	0.82 (0.61–1.10)
Antiplatelet drugs	1.29 (0.97–1.70)	1.24 (0.91–1.68)	0.64 (0.51–0.80)	0.74 (0.56–0.98)
Corticosteroids	0.51 (0.37–0.70)	0.68 (0.49–0.95)	0.65 (0.52–0.83)	0.77 (0.60–0.98)
NSAIDs	0.50 (0.34–0.73)	0.52 (0.35–0.77)	0.57 (0.43–0.75)	0.67 (0.51–0.89)
Comorbidity
Diabetes mellitus	0.80 (0.58–1.11)	0.86 (0.61–1.21)	0.97 (0.77–1.21)	1.04 (0.82–1.31)
Angina, TIA and HF	2.36 (1.65–3.39)	2.45 (1.68–3.58)	1.45 (1.18–1.78)	1.96 (1.56–2.46)

Outcome predictor	PP		SP
Outcome predictor	Unadjusted HR	Adjusted HR	Unadjusted HR	Adjusted HR

Statins	0.57 (0.43–0.75)	0.65 (0.48–0.88)	0.47 (0.38–0.58)	0.66 (0.52–0.84)
Age	1.05 (1.03–1.06)	1.04 (1.03–1.06)	1.03 (1.02–1.04)	1.02 (1.00–1.03)
Male/female	1.06 (0.81–1.40)	1.14 (0.85–1.53)	0.83 (0.67–1.02)	0.89 (0.71–1.12)
Baseline TC concentration (mmol/l)	0.99 (0.89–1.10)	1.08 (0.96–1.21)	1.00 (0.94–1.08)	1.00 (0.92–1.08)
Social economic status
1 (most deprived)	1.00	1.00	1.00	1.00
2–3	0.63 (0.45–0.87)	0.54 (0.38–0.75)	1.08 (0.85–1.37)	0.96 (0.75–1.22)
4–5 (most affluent)	0.78 (0.55–1.08)	0.62 (0.44–0.88)	0.85 (0.65–1.11)	0.78 (0.59–1.02)
Concurrent use of drugs
Analgesics	0.64 (0.48–0.85)	0.69 (0.50–0.94)	0.49 (0.40–0.61)	0.50 (0.40–0.63)
Positive inotropic drugs	1.94 (1.33–2.83)	1.71 (1.11–2.61)	1.28 (1.03–1.60)	0.99 (0.77–1.29)
Diuretics	0.95 (0.70–1.27)	0.86 (0.61–1.21)	0.96 (0.72–1.27)	1.10 (0.81–1.49)
Antiarrhythmic drugs	1.11 (0.46–2.69)	0.71 (0.29–1.78)	0.80 (0.54–1.19)	0.70 (0.47–1.05)
β-Adrenoceptor blocking drugs	0.79 (0.60–1.05)	0.78 (0.58–1.05)	0.51 (0.41–0.63)	0.59 (0.47–0.75)
Hypertension and HF	0.67 (0.51–0.88)	0.82 (0.60–1.21)	0.55 (0.44–0.68)	0.70 (0.55–0.88)
Nitrates and calcium-channel blockers	0.85 (0.64–1.13)	1.03 (0.75–1.41)	0.62 (0.49–0.79)	0.95 (0.73–1.23)
Anticoagulants	1.14 (0.79–1.64)	1.01 (0.67–1.53)	0.94 (0.74–1.19)	0.82 (0.61–1.10)
Antiplatelet drugs	1.29 (0.97–1.70)	1.24 (0.91–1.68)	0.64 (0.51–0.80)	0.74 (0.56–0.98)
Corticosteroids	0.51 (0.37–0.70)	0.68 (0.49–0.95)	0.65 (0.52–0.83)	0.77 (0.60–0.98)
NSAIDs	0.50 (0.34–0.73)	0.52 (0.35–0.77)	0.57 (0.43–0.75)	0.67 (0.51–0.89)
Comorbidity
Diabetes mellitus	0.80 (0.58–1.11)	0.86 (0.61–1.21)	0.97 (0.77–1.21)	1.04 (0.82–1.31)
Angina, TIA and HF	2.36 (1.65–3.39)	2.45 (1.68–3.58)	1.45 (1.18–1.78)	1.96 (1.56–2.46)

This Feature Is Available To Subscribers Only